Memantine Treatment Study of Pathological Gambling
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine
in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive
10 weeks of open-label treatment with memantine. The hypothesis to be tested is that
memantine will be effective and well tolerated in patients with PG. We hypothesize that
memantine will reduce the severity of gambling symptoms and improve patients' overall
functioning. This study will provide needed data on the treatment of a disabling disorder
that currently lacks a clearly effective treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Forest Laboratories University of Minnesota University of Minnesota - Clinical and Translational Science Institute